Lipid levels and the use of lipid-lowering agents in England and Scotland
- 1 December 2004
- journal article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 11 (6), 484-488
- https://doi.org/10.1097/00149831-200412000-00007
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary InterventionA Randomized Controlled TrialJAMA, 2002
- Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studiesBMJ, 2002
- Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional surveyBMJ, 2000
- Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk menHeart, 1999
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Impact of Diabetes on Mortality After the First Myocardial InfarctionDiabetes Care, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia AssociationPublished by Oxford University Press (OUP) ,1993